Home to pharma giants Roche and Novartis, the Swiss city along the Rhine River is attracting biotech companies of all sizes that are driving life sciences innovation.
The partnership adds 10 GMP production lines and 350,000 liters of reactor capacity to support clinical- through commercial-scale active pharmaceutical ingredient supply.
The deal grants Earendil exclusive rights to WuXi’s payload-linker platform, combining AI-driven antibody discovery with integrated antibody-drug conjugate manufacturing.
The CDMO will present on process analytical technology, digital manufacturing, and real-time analytics as part of FDA’s CBER Advanced Manufacturing Seminar Series.
Learn how different temperature monitoring tools reveal what your pharmaceutical shipments experienced and how to choose the right one to protect your supply chain.
Innovators are redefining bioreactor technology, cell and gene therapy manufacturing, pharmaceutical packaging, and small molecule APIs. Pharma Manufacturing’s 2025 Innovation...
Faced with increasing quality, risk, and talent pressures, pharma manufacturers are embracing smart manufacturing and automation to overcome these challenges. Find out in this...
Advancements in cleanroom technology are redefining pharmaceutical manufacturing with energy-efficient HVAC, sustainable materials, and intelligent airflow. However, much more...
Industrializing the manufacturing of these complex therapies is critical to ensure scalability and commercial viability, says the Alliance for Regenerative Medicine.
Large pharmaceutical companies have promised to invest more than $370 billion over the next five years in the U.S., driven by Trump’s threat of pharma-specific tariffs.
The deal is a win for Britain’s beleaguered pharma sector and comes after President Trump threatened to impose 100% tariffs on branded drugs imported to the U.S.
To counter the Chinese government’s investment, the U.S. must make a coordinated effort to grow biomanufacturing base, argues a bipartisan commission created by Congress.
The pharma giant has added to its inventory of orforglipron in anticipation of a favorable regulatory decision by the U.S. Food and Drug Administration.
Raleigh-Cary and Durham-Chapel Hill secured the first and third spots, respectively, as the nation’s most competitive markets for the production of therapeutic biologics.
SymphonX, which runs all downstream unit operations in both fed-batch and continuous processes, will serve customers at Fujifilm’s Billingham manufacturing facility.
As artificial intelligence tools proliferate, the real challenge is not generating ideas but turning them into chemically feasible and manufacturable paths.
Manufacturers face growing pressure to align drug design, production strategy, logistics, and workforce planning to ensure reliable, at-scale delivery.
Report finds 40 states and Puerto Rico are offering sales and tax exemptions to lower costs for new biomanufacturing and research and development facilities.
Software platforms can seamlessly integrate with emerging technologies to unlock efficiencies, strengthen sustainability and enable proactive prevention of disruptions.
Pharmaceutical manufacturing operates in a high-stakes environment where regulatory compliance, product integrity, and operational uptime are non-negotiable. As the industry becomes...
Built-in ability to meet data integrity standards should be a central focus when selecting control systems and manufacturing execution systems for pharma manufacturing
Despite the legal setback for President Trump’s country-specific tariffs, he retains the authority to impose Section 232 tariffs on pharmaceuticals imported to the U.S.
The agency will select new pharma manufacturing facilities for the pilot aimed at reducing inspection-related delays and creating a more predictable regulatory pathway.
Production is highly concentrated globally making lower- and middle-income regions vulnerable to supply shocks, regulatory bottlenecks, and slow pandemic response.
Atradius and GlobalData see Britain as having a competitive advantage in attracting pharmaceutical production, thanks to tariff exemptions for drug exports to U.S.
Biomanufacturing scaling and supply chain resilience are top priorities for biopharma companies as they look to mitigate risks and capitalize on growth opportunities.
The industry requires local resilience and flexibility in a complex global landscape, according to separate reports from consulting firms Deloitte and West Monroe.
